A SURGICAL WINDOW-OF-OPPORTUNITY CLINICAL TRIAL EVALUATING THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH GLIOMA

被引：0

作者：

Singh, Kirit ^{[1
]}

Hotchkiss, Kelly ^{[2
]}

Foster, Matthew ^{[3
]}

Railton, Chelsea ^{[4
]}

Blandford, Emily ^{[2
]}

Thomas, Elizabeth ^{[5
]}

Miller, Elizabeth S. ^{[6
]}

Ashley, David ^{[7
]}

Desjardins, Annick

Friedman, Henry ^{[8
]}

Johnson, Margaret O. ^{[6
]}

Friedman, Allan ^{[9
]}

Keir, Steve ^{[10
]}

Herndon, James ^{[11
]}

Sampson, John ^{[2
]}

Li, Chuan-Yuan ^{[12
]}

Fecci, Peter ^{[9
]}

Patel, Anoop ^{[9
]}

Khasraw, Mustafa ^{[4
]}

机构：

[1] Duke Brain Tumor Immunotherapy Program, Durham, NC USA

[2] Duke Univ, Durham, NC USA

[3] Duke Prote & Metabol core, Durham, NC USA

[4] Duke Brain Tumor Immunotherapy Program, Durham, NC USA

[5] Duke Univ Brain Tumor Biorepository, Durham, NC USA

[6] Duke Univ, Sch Med, Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[7] Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA

[8] Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[9] Duke Univ, Dept Neurosurg, Durham, NC USA

[10] Duke Univ, Sch Med, Durham, NC USA

[11] Duke Canc Inst, Dept Biostat, Durham, NC USA

[12] Duke Canc Inst, Durham, NC USA

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CTIM-10

引用

页数：1

共 50 条

[31] Impact of evolocumab, a PCSK9 inhibitor, withdrawing from regular ldl-apheresis therapy in patients with heterozygous familial hypercholesterolemia
Kawashiri, M.
Higashikata, T.
Nohara, A.
Nakanishi, C.
Tada, H.
Okada, H.
Yamagishi, M.
EUROPEAN HEART JOURNAL, 2017, 38 : 1331 - 1331
[32] Effects of Long-term, Monthly Administration of the Pcsk9 Inhibitor Evolocumab (Amg 145) in Patients with Dysglycemia or Metabolic Syndrome
Henry, R. R.
Holman, R. R.
Giugliano, R. P.
Raal, F. J.
Sullivan, D.
Honarpour, N.
Nelson, P.
Elliott, M.
Liu, T.
Wasserman, S. M.
Somaratne, R.
Koren, M. J.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2014, 21 : S8 - S8
[33] A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice
Knickelbine, Thomas
Jia, Lori
White, Susan K.
Garberich, Ross F.
Oberembt, Sandra J.
Wills, Samantha
Miedema, Michael D.
Brilakis, Emmanouil S.
JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (02) : 265 - 271
[34] SEX-RELATED DIFFERENCE IN THE REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB: INSIGHTS FROM GLAGOV
King, Peta
Puri, Rishi
Ballantyne, Christie
Cho, Leslie
Brennan, Danielle
Kassahun, Helina
Somaratne, Ransi
Wasserman, Scott
Nissen, Steven
Nicholls, Stephen
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1077 - 1077
[35] Marked Elevation of Mature PCSK9 Levels and Inversely Decrease of Furin-cleaved PCSK9 Levels After Administration of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction
Nakamura, Akihiro
Kagaya, Yuta
Kanazawa, Masanori
Kondo, Masateru
Sato, Kenjiro
Endo, Hideaki
Nozaki, Eiji
CIRCULATION, 2019, 140
[36] Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
de Groot, John
Penas-Prado, Marta
Alfaro-Munoz, Kristin
Hunter, Kathy
Pei, Be Lian
O'Brien, Barbara
Weathers, Shiao-Pei
Loghin, Monica
Kamiya Matsouka, Carlos
Yung, W. K. Alfred
Mandel, Jacob
Wu, Jimin
Yuan, Ying
Zhou, Shouhao
Fuller, Gregory N.
Huse, Jason
Rao, Ganesh
Weinberg, Jeffrey S.
Prabhu, Sujit S.
McCutcheon, Ian E.
Lang, Frederick F.
Ferguson, Sherise D.
Sawaya, Raymond
Colen, Rivka
Yadav, Shalini S.
Blando, Jorge
Vence, Luis
Allison, James
Sharma, Padmanee
Heimberger, Amy B.
NEURO-ONCOLOGY, 2020, 22 (04) : 539 - 549
[37] Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials
Eslami, Seyyed Majid
Nikfar, Shekoufeh
Ghasemi, Maryam
Abdollahi, Mohammad
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2017, 20 : 81 - 96
[38] Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma
Odia, Yazmin
Koschmann, Carl Johannes
Tarapore, Rohinton
Allen, Jeffrey
Zaky, Wafik Tharwat
Hall, Matthew David
Daghistani, Doured
Khatib, Ziad
Aguilera, Dolly
MacDonald, Tobey J.
de Blank, Peter
McGovern, Susan L.
Mueller, Sabine
Kline, Cassie
Vitanza, Nicholas A.
Allen, Joshua E.
Gardner, Sharon L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] Safety and Efficacy of PCSK9 Inhibitor Treatment in Heart Transplant Patients
Di Nora, Concetta
Sponga, Sandro
Livi, Ugolino
TRANSPLANTATION, 2019, 103 (03) : E58 - E58
[40] PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab
Dahagam, Chanukya
Goud, Aditya
Abdelqader, Abdelhai
Hendrani, Aditya
Feinstein, Matthew J.
Qamar, Arman
Joshi, Parag H.
Swiger, Kristopher J.
Byrne, Kathleen
Quispe, Renato
Jones, Steven R.
Blumenthal, Roger S.
Martin, Seth S.
FUTURE CARDIOLOGY, 2016, 12 (02) : 139 - 148

← 1 2 3 4 5 →